AvertD and AvertD Buccal Sample Collection Kit
AutoGenomics, Inc. · Decision date Apr 10, 2026
What did the FDA approve?
FDA records P230032/S004 as a supplement to PMA P230032, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 10, 2026.
FDA approval order statement
Approval for the addition of venous whole blood as sample type for use with the AvertD test.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Clinical Toxicology
- Decision date
- Apr 10, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P230032/S004
- Regulatory pathway
- PMA supplement
- Applicant
- AutoGenomics, Inc.
- Product code
- QZH
- Decision code
- APPR
- Decision date
- Apr 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Opioid use disorder genetic risk variant detection system and collection kit.
- Applicant
- AutoGenomics, Inc.
- Product code
- QZH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230032/S004 received
Application receipt date recorded by FDA.
P230032/S003 · Related supplement
AvertD and AvertD Buccal Sample Collection Kit
P230032/S004 · FDA decision
Real-Time Process
P230032/S005 · Related supplement
AvertD and AvertD Buccal Sample Collection Kit
Timeline entries are records held by MedtechLedger for P230032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AvertD and AvertD Buccal Sample Collection KitP230032/S003 | AutoGenomics, Inc. | PMA supplement | Jan 29, 2026 | FDA |
AvertD and AvertD Buccal Sample Collection KitP230032/S005 | AutoGenomics, Inc. | PMA supplement | May 20, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
AutoGenomics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1600 Faraday Ave., Carlsbad, CA, 92008
Sources and methodology
- Original FDA record: P230032/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
